X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NP137 is a humanized monoclonal antibody of isotype IgG1 directed against netrin-1. Most types of tumors produce an abnormal amount of dependence receptors’ ligands, which prevents cells from apoptosis.
Lead Product(s): NP137,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: NP137
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Details:
NP137 is a humanized monoclonal antibody of isotype IgG1 directed against netrin-1. Most types of tumors produce an abnormal amount of dependence receptors’ ligands, which prevents cells from apoptosis.
Lead Product(s): NP137,Undisclosed
Therapeutic Area: Oncology Product Name: NP137
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
Preclinical studies show NP137 to have an anti-cancer effect as a monotherapy as well as synergistic effects in combination with chemotherapy or immune checkpoint inhibitors.
Lead Product(s): NP137
Therapeutic Area: Oncology Product Name: NP137
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Orano
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 20, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
